Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Burning Rock Biotech (BNR) Net Income towards Common Stockholders (2019 - 2025)

Burning Rock Biotech has reported Net Income towards Common Stockholders over the past 7 years, most recently at -$2.2 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 80.57% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached -$7.8 million, up 83.85%, while the annual FY2025 figure was -$2.2 million, 80.83% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was -$2.2 million at Burning Rock Biotech, up from -$2.4 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$1.4 million in Q2 2025 and troughed at -$41.2 million in Q1 2022.
  • A 5-year average of -$20.8 million and a median of -$23.4 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest five-year swings in Net Income towards Common Stockholders: tumbled 131.53% in 2021 and later skyrocketed 90.89% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$39.4 million in 2021, then increased by 20.45% to -$31.4 million in 2022, then grew by 27.12% to -$22.8 million in 2023, then surged by 50.47% to -$11.3 million in 2024, then skyrocketed by 80.57% to -$2.2 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for BNR at -$2.2 million in Q4 2025, -$2.4 million in Q3 2025, and -$1.4 million in Q2 2025.